Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Check market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,399,101

« Back to Dashboard
Patent 6,399,101 protects LEVO-T and is included in one NDA.

This patent has eight patent family members in seven countries.

Summary for Patent: 6,399,101

Title: Stable thyroid hormone preparations and method of making same
Abstract:Provided is a pharmaceutical preparation of thyroid hormone and a process of making a tablet formulation of the pharmaceutical preparation using direct compression. In a preferred embodiment, the pharmaceutical preparation comprises levothyroxine sodium and silicified microcrystalline cellulose.
Inventor(s): Frontanes; Ramon A. (Caguas, PR), Bruno; Maria S. (Guaynabo, PR), Garcia; Hector L. (Cidra, PR), Simamora; Pahala (Cardova, TN), Perez; Maria A. (Aguas Buenas, PR)
Assignee: Mova Pharmaceutical Corp. (Caguas, PR)
Application Number:09/538,461
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form; Use;
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 32nd percentile
Forward Citations: 7th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Alara Pharm
levothyroxine sodium
TABLET;ORAL021342-001Mar 1, 2002RXNo6,399,101► subscribe
Alara Pharm
levothyroxine sodium
TABLET;ORAL021342-002Mar 1, 2002RXNo6,399,101► subscribe
Alara Pharm
levothyroxine sodium
TABLET;ORAL021342-003Mar 1, 2002RXNo6,399,101► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,399,101

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia2001252953► subscribe
Australia5295301► subscribe
Brazil0109736► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.